Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

11.54 (USD) • At close September 6, 2024
Bedrijfsnaam Enanta Pharmaceuticals, Inc.
Symbool ENTA
Munteenheid USD
Prijs 11.54
Beurswaarde 244,516,444
Dividendpercentage 0%
52-weken bereik 8.08 - 17.8
Industrie Biotechnology
Sector Healthcare
CEO Dr. Jay R. Luly Ph.D.
Website https://www.enanta.com

An error occurred while fetching data.

Over Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories

Vergelijkbare Aandelen

Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

ACRS

1.17 USD

Kura Oncology, Inc. logo

Kura Oncology, Inc.

KURA

19.29 USD

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

5.04 USD

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

41.12 USD

FibroGen, Inc. logo

FibroGen, Inc.

FGEN

0.39 USD

Cutera, Inc. logo

Cutera, Inc.

CUTR

0.687 USD

Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

SNDX

19.1 USD

Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

KROS

52.51 USD

REGENXBIO Inc. logo

REGENXBIO Inc.

RGNX

11.48 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)